Clinical trial
An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours
NCT03008018 is registered in ClinicalTrials.gov with Karus Therapeutics Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours
- Lead sponsor
- Karus Therapeutics Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 7, 2017
- Completion date
- June 10, 2020
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumor, adult